DFCI's ASCO 2019 Update on Metastatic Urothelial Carcinoma: Analysis of Ongoing Clinical Trials - Enfortumab Vedotin Monotherapy, Gemcitabine/Cisplatin+Bevacizumab, Maintenance Pembrolizumab, and Coexpression Extrapolation (COXEN)
By
Dana-Farber Cancer Institute
FEATURING
Guru Sonpavde
By
Dana-Farber Cancer Institute
FEATURING
Guru Sonpavde
Login to view comments.
Click here to Login